These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12872511)

  • 1. [Dendritic cell vaccine is a hope for alternative treatment of HIV infection].
    Kahl U
    Lakartidningen; 2003 Jun; 100(25):2224. PubMed ID: 12872511
    [No Abstract]   [Full Text] [Related]  

  • 2. Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines.
    Ahlers JD; Belyakov IM
    Trends Mol Med; 2009 Jun; 15(6):263-74. PubMed ID: 19487159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
    Egan MA
    Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
    [No Abstract]   [Full Text] [Related]  

  • 4. May immunization strategies that target dendritic cells really offer advantages for HIV-1?
    Costa P; Beltrame A; De Maria A
    AIDS; 2006 Jun; 20(9):1351-2. PubMed ID: 16816576
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic mobilization of antigen presenting cells, with a chimeric Flt-3 and G-CSF receptor agonist, during immunization of Macaca mulatta with HIV-1 antigens is insufficient to modulate immune responses or vaccine efficacy.
    Koopman G; Mortier D; Niphuis H; Farese AM; Kahn LE; Mann D; Wagner R; MacVittie TJ; Woulfe SL; Heeney JL
    Vaccine; 2005 Jul; 23(33):4195-202. PubMed ID: 15896883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failed HIV vaccine may have increased vulnerability to infection.
    Clin Infect Dis; 2008 Jan; 46(1):iii. PubMed ID: 18181273
    [No Abstract]   [Full Text] [Related]  

  • 7. Thailand's Prime-Boost HIV Vaccine Phase III.
    Trinvuthipong C
    Science; 2004 Feb; 303(5660):954-5. PubMed ID: 14963308
    [No Abstract]   [Full Text] [Related]  

  • 8. Support for the RV144 HIV vaccine trial.
    Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice.
    Kawamura M; Wang X; Uto T; Sato K; Ueno M; Akagi T; Hiraishi K; Matsuyama T; Akashi M; Baba M
    J Med Virol; 2005 May; 76(1):7-15. PubMed ID: 15778965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Policy rebuttal. HIV vaccine trial justified.
    McNeil JG; Johnston MI; Birx DL; Tramont EC
    Science; 2004 Feb; 303(5660):961. PubMed ID: 14963313
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells.
    Kran AM; Sørensen B; Sommerfelt MA; Nyhus J; Baksaas I; Kvale D
    AIDS; 2006 Feb; 20(4):627-30. PubMed ID: 16470131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
    Fanales-Belasio E; Moretti S; Fiorelli V; Tripiciano A; Pavone Cossut MR; Scoglio A; Collacchi B; Nappi F; Macchia I; Bellino S; Francavilla V; Caputo A; Barillari G; Magnani M; Laguardia ME; Cafaro A; Titti F; Monini P; Ensoli F; Ensoli B
    J Immunol; 2009 Mar; 182(5):2888-97. PubMed ID: 19234184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine.
    López A; van der Lubbe N; Sánchez-Palomino S; Arnedo M; Nomdedeu M; Castro P; Guilà M; Maleno MJ; García F; Gallart T; Gatell JM; Plana M
    Vaccine; 2009 Oct; 27(44):6166-78. PubMed ID: 19712765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?
    Smith RJ; Schwartz EJ
    Math Biosci; 2008 Apr; 212(2):180-7. PubMed ID: 18359048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model.
    Nehete PN; Nehete BP; Manuri P; Hill L; Palmer JL; Sastry KJ
    Vaccine; 2005 Mar; 23(17-18):2154-9. PubMed ID: 15755586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US and Thai Governments defend HIV/AIDS vaccine trial in Thailand.
    Agnew B
    Bull World Health Organ; 2004 Mar; 82(3):231. PubMed ID: 15112014
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.
    Lu W; Arraes LC; Ferreira WT; Andrieu JM
    Nat Med; 2004 Dec; 10(12):1359-65. PubMed ID: 15568033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Here's my arm. My personal experience participating in an HIV-vaccine trial.
    Abitol G
    Body Posit; 2004; 17(4):22-3. PubMed ID: 15929211
    [No Abstract]   [Full Text] [Related]  

  • 19. Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection.
    Egan MA
    AIDS Res Hum Retroviruses; 2004 Aug; 20(8):794-806. PubMed ID: 15320982
    [No Abstract]   [Full Text] [Related]  

  • 20. Adaptive clinical trial designs proposed to accelerate development of HIV vaccines.
    Expert Rev Vaccines; 2011 Jun; 10(6):717. PubMed ID: 21692694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.